What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Biochemistry
- Composite material
His primary areas of investigation include Transdermal, Nanotechnology, Biomedical engineering, Drug delivery and Surgery.
His Transdermal study results in a more complete grasp of Pharmacology.
He has included themes like Biophysics, Calcein and Polymer in his Nanotechnology study.
Mark R. Prausnitz interconnects Substrate, Penetration, Permeability, Pharmaceutical technology and Interstitial fluid in the investigation of issues within Biomedical engineering.
His Drug carrier study in the realm of Drug delivery connects with subjects such as Delivery system.
His work deals with themes such as Internal medicine, Adverse effect and Intramuscular injection, which intersect with Surgery.
His most cited work include:
- Transdermal drug delivery (1946 citations)
- Microneedles for transdermal drug delivery. (997 citations)
- Current status and future potential of transdermal drug delivery (971 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Biomedical engineering, Transdermal, Drug delivery, Nanotechnology and Biophysics.
Mark R. Prausnitz combines subjects such as Surgery and Suprachoroidal space with his study of Biomedical engineering.
Transdermal is a subfield of Pharmacology that Mark R. Prausnitz studies.
As a part of the same scientific family, Mark R. Prausnitz mostly works in the field of Drug delivery, focusing on Sclera and, on occasion, Choroid.
Mark R. Prausnitz combines topics linked to Polymer with his work on Nanotechnology.
His studies deal with areas such as Membrane, Calcein, Viability assay, Intracellular and Electroporation as well as Biophysics.
He most often published in these fields:
- Biomedical engineering (30.62%)
- Transdermal (23.92%)
- Drug delivery (21.53%)
What were the highlights of his more recent work (between 2015-2021)?
- Biomedical engineering (30.62%)
- Vaccination (16.75%)
- Immune system (9.33%)
In recent papers he was focusing on the following fields of study:
Mark R. Prausnitz mostly deals with Biomedical engineering, Vaccination, Immune system, Virology and Drug delivery.
His work carried out in the field of Biomedical engineering brings together such families of science as Ex vivo, Targeted drug delivery, Transdermal and Choroid, Suprachoroidal space.
Mark R. Prausnitz studies Transdermal patch, a branch of Transdermal.
His Vaccination research incorporates themes from Antibody, Immunization and Immunogenicity.
His Immune system research integrates issues from Adjuvant and Viral load.
His Drug delivery study combines topics in areas such as Ophthalmology, Iontophoresis and Stratum corneum.
Between 2015 and 2021, his most popular works were:
- The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial (150 citations)
- Engineering Microneedle Patches for Vaccination and Drug Delivery to Skin (131 citations)
- Microneedle patches for vaccination in developing countries. (97 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Biochemistry
- Composite material
The scientist’s investigation covers issues in Biomedical engineering, Vaccination, Virology, Transdermal and Drug delivery.
His biological study spans a wide range of topics, including Iontophoresis, Distribution and Interstitial fluid.
His work investigates the relationship between Distribution and topics such as Fluorescein isothiocyanate that intersect with problems in Nanotechnology.
Mark R. Prausnitz has included themes like Antibody, Immune system and Intramuscular injection in his Vaccination study.
His study in Transdermal focuses on Transdermal patch in particular.
Mark R. Prausnitz studies Drug delivery, focusing on Targeted drug delivery in particular.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
